|
Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in advanced solid tumors. |
|
|
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; Onc.AI; Pyxis; Tempest Therapeutics |
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alphamab; Array BioPharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Compugen; CStone Pharmaceuticals; Eisai; EMD Serono; Incyte; Janssen; Merck; Mersana; Nektar; Novartis; Partner Therapeutics; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; Spring Bank; Synlogic; Tempest Therapeutics; Tesaro; TTC Oncology; Werewolf Therapeutics; Xencor; Xilio Therapeutics |
Research Funding - Abbvie (Inst); Agios; Array BioPharma; Astellas Pharma; Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals; Corvus Pharmaceuticals (Inst); EMD Serono; Immatics; Incyte (Inst); Kadmon; Macrogenics (Inst); Merck (Inst); Moderna Therapeutics; Nektar; Spring bank; Trishula Therapeutics; Xencor (Inst) |
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof) |
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Pfizer; Sanofi |
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Gan & Lee (Inst); GlaxoSmithKline (Inst); Glyconex (Inst); Immunocore (Inst); Intensity Therapeutics (Inst); Iovance Biotherapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Navire (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Seagen (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sumitomo Group (Inst); Takeda (Inst); Targovax (Inst) |
(OPTIONAL) Uncompensated Relationships - Takeda |
|
|
Stock and Other Ownership Interests - Celldex; Celldex (I) |
Consulting or Advisory Role - Amgen; Iovance Biotherapeutics; Merck; Roche |
|
|
Employment - Alvogen (I); Kadmon |
Stock and Other Ownership Interests - Kadmon; Lilly; Teva (I) |
Patents, Royalties, Other Intellectual Property - Flt-3 antibody (Inst); PD1 antibody and I15 fusions (Inst); PDL1 antibody and fusions (Inst); VEGFR2 antibody (Inst) |
|
|
|
Stock and Other Ownership Interests - Kadmon |
|
|
|
Stock and Other Ownership Interests - Kadmon |
|
Research Funding - Kadmon |
Patents, Royalties, Other Intellectual Property - Patent |
Travel, Accommodations, Expenses - Kadmon |
|
|
|
Stock and Other Ownership Interests - Kadmon |
Travel, Accommodations, Expenses - Kadmon |
|
|
|
|
|
Employment - Jounce Therapeutics; Kadmon |
Stock and Other Ownership Interests - Jounce Therapeutics; Kadmon |
Travel, Accommodations, Expenses - Jounce Therapeutics |
|
|
|
Research Funding - Kadmon (Inst) |
Travel, Accommodations, Expenses - Kadmon |
|
|
No Relationships to Disclose |